Tranexamic Acid vs Hydroquinone for Melasma: A Complete Comparison Guide

Tranexamic acid and hydroquinone both lighten melasma, but they act at different points in the pigmentation pathway. Hydroquinone inhibits tyrosinase, the enzyme that produces melanin inside the melanocyte. Tranexamic acid works upstream, dampening the plasmin-driven signalling that tells melanocytes to switch on—including the vascular and inflammatory triggers that make melasma so persistent. Understanding that difference explains why one is a short-course corrective agent and the other is increasingly used for long-term control, and why Korean dermatologists frequently combine them rather than choosing between them.

Hydroquinone: Direct Enzyme Inhibition

Hydroquinone is a phenolic compound that competitively inhibits tyrosinase and is cytotoxic to melanocytes at higher concentrations. It has been the reference standard for melasma for decades and remains, by most published comparisons, the single most potent topical depigmenting agent available.

Its limitation is not efficacy but tolerability and duration. Prolonged uninterrupted use is associated with irritant dermatitis and, rarely, exogenous ochronosis—a paradoxical blue-grey discolouration that is difficult to reverse. For this reason most protocols use it in defined cycles, commonly a course of several months followed by a rest period, rather than indefinitely. Regulatory status differs by country; in some markets it is prescription-only, and over-the-counter availability varies.

Tranexamic Acid: Interrupting the Signal

Tranexamic acid is an antifibrinolytic originally used to reduce bleeding. Its pigmentary effect comes from inhibiting plasminogen activation in keratinocytes, which reduces downstream arachidonic acid and prostaglandin signalling to melanocytes. It also appears to reduce the dermal vascularity and mast cell activity now recognised as a core feature of melasma pathology, not an incidental one.

This matters because melasma is not purely a melanocyte disorder. The vascular component explains why it flares with heat, hormones, and ultraviolet exposure, and why treatments that only inhibit tyrosinase often relapse. Tranexamic acid is used topically, as intradermal microinjection, and orally—the last under physician supervision only.

Head-to-Head: What the Comparative Data Suggests

Published comparisons generally indicate that hydroquinone produces faster and somewhat greater initial lightening, while tranexamic acid produces comparable results over longer horizons with a more favourable tolerability profile and, in several series, lower relapse rates. Combination regimens often outperform either agent alone.

• Onset of visible change: commonly 4 to 8 weeks for hydroquinone; often 8 to 12 weeks for topical tranexamic acid.

• Typical hydroquinone course length: frequently limited to approximately 3 to 6 months before a rest period.

• Oral tranexamic acid trials in melasma commonly run 8 to 12 weeks at low doses, under medical supervision.

• Relapse after stopping either agent is common—reported in a substantial proportion of patients within 6 months without maintenance and strict photoprotection.

The Safety Conversation That Matters Most: Oral Tranexamic Acid

Oral tranexamic acid is widely discussed online and frequently trivialised. It is an antifibrinolytic drug, and it is contraindicated or requires caution in people with a personal or family history of thrombosis, clotting disorders, active malignancy, or concurrent use of combined oral contraceptives, among other conditions. It should be prescribed only after a medical history is taken, and it should never be sourced informally.

This is the single most important point in this article. Topical formulations do not carry the same systemic considerations, which is why they are often the reasonable starting point for patients without a supervising physician.

What Most Melasma Articles Get Wrong: Sequence and Photoprotection

The common error is treating melasma as a lightening problem rather than a suppression problem. Any agent that lightens will be defeated by ultraviolet and visible light exposure. Visible light in particular—including blue light—drives pigmentation in deeper skin phototypes, which is why tinted sunscreens containing iron oxides are frequently recommended over transparent chemical filters for melasma specifically.

A defensible sequence looks like: establish rigorous photoprotection first, add a topical agent second, consider procedural adjuncts third, and only then discuss oral therapy with a physician. Reversing that order produces the familiar cycle of aggressive treatment followed by rebound. See our detailed explanation of

how sunscreen actually works and how to choose SPF for treated skin.

Where Lasers Fit — and Where They Backfire

Melasma is notoriously heat-sensitive. Aggressive laser treatment can worsen it, and rebound pigmentation after resurfacing is a well-documented pattern in Asian skin. Low-fluence approaches are used by experienced clinicians, but as an adjunct to medical therapy rather than a replacement for it. Our guide on

preventing post-inflammatory hyperpigmentation after laser on Asian and deeper skin explains the mechanism behind that risk.

Frequently Asked Questions

Can I use both agents at the same time?

Combination protocols exist and are common in dermatology practice, often pairing a hydroquinone-containing formulation with topical tranexamic acid, or cycling between them. This should be structured by a dermatologist rather than self-assembled, because irritation from stacked actives can itself trigger pigmentation.

How long until I see results?

Melasma responds slowly. Meaningful change is usually assessed at 8 to 12 weeks, and photographs under consistent lighting are far more reliable than mirror impressions.

Is tranexamic acid safe during pregnancy?

Melasma commonly appears or worsens in pregnancy, but pharmacological treatment during pregnancy and breastfeeding requires physician guidance. Photoprotection and gentle skincare are typically the mainstay until after delivery.

What about niacinamide, azelaic acid, and cysteamine?

All are legitimate alternatives or adjuncts, particularly for patients who cannot tolerate hydroquinone. Azelaic acid is often used in pregnancy-adjacent situations under medical advice; cysteamine has growing evidence but a distinctive odour that affects adherence.

Will melasma ever be permanently cured?

Current evidence frames melasma as a chronic, relapsing condition that is managed rather than cured. Long-term maintenance and photoprotection are part of the treatment, not an optional extra.

Building a Realistic Melasma Plan in Korea

Korean dermatology clinics commonly offer structured melasma programmes combining topical therapy, microinjection, low-fluence device work, and strict photoprotection counselling. Ask which agents are in any compounded preparation you are given, at what concentrations, and what the planned course length and rest period are. Bring your full medication history, including hormonal contraception, before any oral agent is discussed. Individual responses vary and no protocol can be guaranteed; treatment should be directed by a licensed dermatologist.

Sources

Korea Health Industry Development Institute (KHIDI) | Korean Medical Association (KMA) | PubMed — tranexamic acid versus hydroquinone in melasma

This article is general information, not medical advice. Consult a licensed specialist for guidance specific to your case.